Resveratrol

Oct. 27, 2025 -- Jupiter Neurosciences, Inc (“JUNS” or the “Company”) (NASDAQ: JUNS), a clinical stage biopharmaceutical company that is advancing a therapeutic pipeline targeting central nervous system (“CNS”) disorders, while also expanding into the consumer longevity market with its Nugevia™ product line, today announced that it has entered into two strategic financing agreements with an affiliate of Yorkville Advisors Global, LP (“Yorkville”), providing JUNS with the potential to access up to $20 million in capital (the “Financing”), subject to certain conditions and limitations. The Financing includes: A $6 million pre-paid advance, with an initial $4 million advance funded at signing, on October 24, 2024 and evidenced by a convertible promissory note with a fixed conversion price of $1.50; and An additional $14 million available under the standby equity purchase agreement (“SEPA”), which the Company may use at its discretion over 24 months after signing, subject to an effective registration statement. JUNS intends to use the proceeds from these facilities primarily to support the Phase 2 trial of its lead asset – JOTROL™, a resveratrol delivery platform1 – for the treatment of Parkinson’s disease and to accelerate direct-to-consumer marketing and sales growth of its recently launched nutritional product line Nugevia™. The Company will also use proceeds from the Financing for working capital and other general corporate purposes. Key Terms of Flexible Financing: Pre-paid Advances: $4 million was made available to JUNS upon execution of the agreements and an additional $2 million is anticipated to be paid on the second trading day after the effectiveness of a registration statement covering the resale of the shares of the Company’s outstanding common stock (the “Common Stock”) used to repay the facility (the “Pre-Paid Advances”). Each Pre-Paid Advance will be issued at a 7% original issue discount and bear interest. Each Pre-Paid Advance will also be evidenced by convertible promissory notes. The Pre-paid Advances have a maturity date that is 12 months after the date of signing. To repay each Pre-Paid Advance, JUNS has the option to use cash or shares of Common Stock, issued at a discounted price. Additional Funds Available Under the SEPA: JUNS has the option, but not the obligation, to sell to Yorkville up to $14 million of Common Stock (“Financing Shares”) over the 24-month period after signing. Sales under the SEPA require a registration statement to be declared effective by the SEC. In accordance with the terms of the SEPA, the Company may issue Financing Shares to the Investor at a 3.0% discount to the market price (calculated pursuant to the SEPA) of the Common Stock. All drawdowns under the SEPA, if any, must be applied towards repayment of the outstanding amounts under the convertible promissory notes evidencing the prepaid cash advances until the convertible promissory notes are fully repaid. A more detailed description of the agreements will be filed in a Current Report on Form 8-K that JUNS will file with the SEC. Christer Rosén, Chairman and CEO of JUNS, stated, “We believe this financing will provide us with the capital required to complete the Phase 2 Parkinson’s disease trial and continue to support the launch of our DTC longevity nutraceutical line, Nugevia™. We are grateful for Yorkville’s support at this critical stage of our Company’s growth and look forward to executing on both our projects and business strategy.” Jupiter Neurosciences, Inc. (NASDAQ:JUNS) is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (“CNS”) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia™ brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. Resveratrol is one of the world's most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication. Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer's Disease trial, and Yui et al., Friedreich's Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL™ trials, were published in the Journal of Alzheimer's Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL™ toward a Phase IIa trial in Parkinson's Disease. In addition to its therapeutic applications, JOTROL™ serves as the foundation for Jupiter's Nugevia™ consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia™ introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy. 1 Note to Company: Suggest clarifying what JOTROL is. We’ve added some language but please update as needed The content above comes from the network. if any infringement, please contact us to modify.

Company outlines how nanoengineering approaches may advance studies of mitochondrial function and cellular health. This publication in Frontiers in Aging represents a synthesis of emerging data on mitochondrial nanoengineering, reflecting our commitment to peer-reviewed science and measurable longevity research.” — Thomas Miller, Head of the 64K Cellssense International Research Center LAUSANNE, SWITZERLAND, October 27, 2025 / EINPresswire.com / -- 64K Cellssense announced its Research and Innovation Center published a review article in Frontiers in Aging , a leading Swiss academic journal. The article, titled “Nanoengineered Mitochondria for Mitochondrial Dysfunction and Anti-Aging Interventions,” explores the emerging field of mitochondrial nanoengineering and its implications for maintaining cellular function and energy balance. The review provides a comprehensive overview of recent advances in nanoengineered mitochondria — a rapidly growing focus in life sciences. It details how nanoscale design can support mitochondrial integrity, optimize metabolic efficiency, and enhance resilience under cellular stress. The review offers an international perspective on how nanotechnology is shaping next-generation mitochondrial research, reflecting 64K Cellssense’s contribution to the global dialogue on healthy cellular aging. Within 64K Cellssense’s 12-Dimensional Longevity Framework, mitochondrial performance is studied as a core determinant of cellular function. The review proposes a research framework that integrates nanoengineering strategies to optimize mitochondrial energy systems and mitigate oxidative imbalance at the cellular level. The article also summarizes key natural mitochondrial regulators — including α-ketoglutarate (AKG), ergothioneine (EGT), resveratrol, CoQ10, and selenium — and highlights how nano-delivery approaches may improve their stability and targeted bioavailability in experimental models. Building on these foundational insights, 64K Cellssense continues to develop its proprietary MPNutria ® Nano-Nutrition Delivery Technology, based on metal–phenolic network (MPN) nanostructures — a technology lineage related to the 2025 Nobel Prize -winning research on metal-organic frameworks (MOFs). This technology exemplifies how the brand translates cutting-edge scientific concepts into scalable, experimentally validated applications. While mitochondrial nanoengineering shows considerable potential, the review notes that further research is required to address challenges related to delivery consistency, biological compatibility, and scalable production. The Research and Innovation Center of 64K Cellssense has collaborated on projects with academic and clinical partners in Switzerland, the United States, Australia and China, including, among others, ETH Zurich, Harvard University and Clinique Eden Suisse. Collectively, these efforts reinforce 64K Cellssense’s long-term mission to drive data-driven innovation in cellular health, bridging academic research and practical, scalable applications in life sciences. Anastasia Y. Vitagenix Technology Limited email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.